Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-00489791 SCHEMBL29379715 | 0.92 | PDE5A (1.00) | PDE5AKCNH2 | |
| Pf-00489791 SCHEMBL331279 | 0.92 | PDE5A (1.00) | PDE5AKCNH2 | |
| SCHEMBL331541 | 0.92 | PDE5A (0.72) | PDE5AKCNH2 | |
| SCHEMBL331777 | 0.90 | PDE5A (0.85) | PDE5AKCNH2 | |
| SCHEMBL332775 | 0.90 | PDE5A (0.85) | PDE5AKCNH2 | |
| SCHEMBL331941 | 0.90 | PDE5A (0.68) | PDE5AKCNH2 | |
| SCHEMBL331701 | 0.88 | PDE5A (0.65) | PDE5AKCNH2 | |
| SCHEMBL331423 | 0.88 | PDE5A (0.83) | PDE5AKCNH2 | |
| SCHEMBL332278 | 0.86 | PDE5A (0.89) | PDE5AKCNH2 | |
| SCHEMBL13763146 | 0.86 | PDE5A (0.63) | PDE5AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-1689751-B1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LTD (GB) | 2010-10-20 | — | — | EP | disclosed |
| EP-1689751-B1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LTD (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| US-20090227562-A1 | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor | PFIZER INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2005049616-A1 | 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227562-A1 | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor | PDE4A, PDE12, PDE4B | PDE5A 4/4885KCNH2 2609/4885 |
| US-20090247539-A1 | Novel Pharmaceuticals | ABCB11, PCSK9, SLC10A1 | PDE5A 103/4885KCNH2 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.